Contemporary approaches in aerosolized drug delivery to the lung

Journal of Controlled Release

Volumn 17, Issue 2, 1991, Pages 127-147

  Gupta, Pramod K ^a   Hickey, Anthony J ^b  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aerosols; Controlled release; Drug delivery; Liposomes; Microspheres; Respiratory tract

Indexed keywords

ALPHA 1 ANTITRYPSIN; ATROPINE; CROMOGLYCATE DISODIUM; GENTAMICIN; INTERFERON; LEUPRORELIN; LIDOCAINE; LIPOSOME; NEDOCROMIL SODIUM; ORCIPRENALINE; PENTAMIDINE; RIBAVIRIN;

AEROSOL; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NONHUMAN; PHARMACEUTICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SUSTAINED RELEASE PREPARATION; TECHNIQUE;

EID: 0025943936     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(91)90053-G     Document Type: Review

References (151)

1. Aerosols
2. Aerosols for inhalation therapy
3. Pharmaceutical aerosols
4. Test method for evaluation of loss of prime in metered-dose aerosols
5. Clinical aerosols. II. Therapeutic aerosols
6. Therapeutic aerosols. 2. Drugs available by the inhaled route
7. Aerosols and the Lung
8. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection A randomized double-blind study
9. Nebulised ribavirin for adenovirus pneumonia
10. Comparative absorption of inhaled and intramuscularly administered atropine
11. The physiology of the lung
12. Drug absorption from the lung
13. Long-term retention and clearance of particles inhaled by mammalian species
14. Lung pH and pulmonary absorption of non volatile drugs in the rat
15. Absorption, clearance, and dissolution in the lung
16. Labeling suspended aerosol particles with short-lived radionuclides for determination of particle deposition
17. Radiotracer evaluation of the deposition of drug particles inhaled from a new powder inhaler
18. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline
19. Measurements of pulmonary epithelium permeability in vivo
20. An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption
21. An investigation of size deposition on individual stages of a cascade impactor
22. Factors influencing aerosol deposition in inertial impactors and their effect on particle size characterization
23. Toward improved in vitro spray size characterization for metered dose aerosols
24. A general method for fitting size distributions to multicomponent aerosol data using weighted least squares
25. Deposition and retention models for internal dosimetry of the human respiratory tract
26. Study of the effects of polydispersity on regional deposition in the respiratory tract
27. The effect of the shape of fine particles on the inhalation properties of powder mixtures
28. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols
29. Deposition of aerosols in the respiratory tract
30. Human lung deposition of particles suspended in air or in helium/oxygen mixture
31. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
32. Recent in vivo methods for evaluating the deposition of aerosols in the respiratory tract
33. Perspectives on the biopharmacy of inhalation aerosols
34. Some future perspectives for unit-dose inhalation aerosols
35. An alternative to direct labelling of pressurized bronchodilator aerosol
36. Characterization of pharmaceutical aerosols using inertial collection devices
37. Optimized inhalation aerosols. II. Inertial testing methods for particle size analysis of pressurized inhalers
38. Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein
39. Prediction of drug residence in regions of the human respiratory tract following aerosol inhalations
40. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels
41. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung
42. Inhalation Therapy
43. Clinical aerosols. I. Characterization of aerosols and their diagnostic uses
44. Simulated respiratory system for in vitro evaluation of two inhalation delivery systems using selected steroids
45. Spacer devices used with metered-dose inhalers: breakthrough or gimmick?
46. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols
47. Inhalation aerosols. I. The effects of spherical baffle size and position upon the output of pressurized non-aqueous suspension formulations
48. Response to bronchodilator drug administration by a new reservoir aerosol delivery system and a review of other auxiliary delivery systems
49. Use of spacers to facilitate inhaled corticosteroid treatment of asthma
50. Pulmonary response to a bronchodilator delivered from three different inhalation devices
51. Efficiency of aerosolization from dry powder blends of terbutaline sulphate and lactose NF with different particle size distribution
52. Dry powder aerosols I: a new powder inhalation device
53. The formulation and evaluation of powders for inhalation
54. The size of soluble aerosol particles as a function of the humidity of the air. Application to the human respiratory tract
55. Effect of low and high relative humidity on metered dose bronchodilator solution and powder aerosols
56. Characterization of hygroscopic inhalation aerosols
57. Effect of air humidity on the hydrodynamics of a fluidized bed of particles differing in size
58. Turbuhaler: A new powder inhaler for administration of drugs to the airways
59. Comparisons of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulised solution
60. A new aerosol formulation of sodium cromoglycate compared with conventional powder in the treatment of asthma
61. Clinica comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler
62. In vivo evaluation of the new multiple dose powder inhaler and the rotahaler using the gamma scintigraphy
63. The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler
64. Turbuhaler: a new device for drug powder terbutaline inhalation
65. A new inhaled beta-2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction
66. Ein neues Therapie-prinzip bei nachtlichem Asthma
67. Physiologic effects and serum lidocaine concentrations after inhalation from a compressed gas-powered jet nebulizer
68. Ribavirin small-particle aerosol treatment of influenza
69. Ribavirin aerosol treatment of influenza B virus infection
70. Deposition, clearance and effects of aerosolized amiloride in sheep airways
71. Effect of inhaled natural interferon-alpha in diffuse bronchioalveolar carcinoma
72. Aerosol application of interferon-alpha in the treatment of bronchioalveolar carcinoma
73. Strategies for aerosol therapy of alpha-1-antitrypsin deficiency by the aerosol route
74. Nedocromil sodium is more potent than sodium cromoglycate against AMP-induced bronchoconstriction in atopic asthmatic subjects
75. Acute pulmonary response to cotton bract extract in monkeys: lung function and effects of mediator modifying compounds
76. Inhaled pentamidine. An overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia
77. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia
78. Aerosol pentamidine
79. Use of a new bioassay to study pentamidine pharmacokinetics
80. Distribution of pentamidine in patients with AIDS
81. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes
82. Selective delivery of pentamidine to the lung by aerosol
83. Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systematic absorption, and excretion
84. Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats
85. Quantitative evaluation of targeted drug delivery systems
86. Aerosolized pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome
87. Trimethoprim-Sulphamethoxazole of pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
88. Digital necrosis and disseminated Pneumocystis carinii infection after aerosolized pentamidine prophylaxis
89. Pulmonary delivery of peptide and protein drugs
90. Bioavailability of leuprolide following intratracheal administration to beagle dogs
91. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers
92. Dry aerosol of monodisperse millimicrospheres for ventilation imaging production delivery system and clinical results in comparison with 81 m-krypton and 127-xenon
93. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory agents
94. Mucociliary tracheal transport rates in man
95. Regional mucociliary removal of inhaled particles in smokers with small airways disease
96. Uneven deposition of minimicrospheres in patients with obstructive lung disease
97. Quantitative radioaerosol lung imaging in healthy subjects and in patients with chronic obstructive lung disease
98. Regional deposition of aerosols in health and in airways obstruction: a comparison with krypton-81m ventilation scanning
99. Patterns of deposition of labelled monodispersed aerosols in obstructive lung disease
100. Ventilation-perfusion studies in bronchiectasis
101. Effective penetration of the lung periphery using radioactive aerosols: concise communication
102. An original method for submacroscopic metastases visualization in cases of cancer minimal residual disease
103. Bronchodilator efficacy of liposome formulations of metaproterenol sulfate in the anesthetized guinea pig
104. Particulate systems for drug delivery to the lung
105. The pharmacokinetics of liposomal sodium cromoglycate nebulised to volunteers
106. The stability of liposomes to nebulisation
107. Antiviral therapy with small particle aerosols
108. Activity against rhinoviruses, toxicity and delivery in aerosol of enviroxime in liposomes
109. Small particle aerosols of enviroxime-containing liposomes
110. Studies of hydrophobic microspheres for controlled pulmonary drug delivery
111. Development and characterization of aerosol formulations of biodegradable microspheres for targeted delivery to the lungs
112. Controlled delivery of an antitumor drug: localised action of liposome encapsulated cytosine arabinoside administered via a respiratory system
113. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase & superoxide dimutase
114. Pulmonary absorption of liposome-encapsulated 6-carboxyfluorescein
115. Peptidyl carbamates as novel elastase inhibitors lung delivery by poly (glycolic acid) microspheres
116. 1
117. Liposome encapsulation attenuates the pulmonary irritation caused by nicotine aerosol inhalation
118. Preparation and characterization of disodium fluorescein powders in association with lauric and capric acids
119. Practical aspects of aerosol characterization in an environment of controlled temperature and relative humidity
120. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity
121. Effect of non-hygroscopic surfactant coating upon fluorescein absorption from the respiratory tract
122. The effect of hydrophobic coatings upon the behavior of pharmaceutical aerosol powders
123. Method for evaluation of suspension characteristics relevant to metered dose inhaler formulations
124. Stratospheric sinl for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone
125. Aerosol Inhalers
126. Some future perspectives for unit-dose inhalation aerosols
127. Protection against pulmonary oxygen toxicity in rats by intratracheal administration of liposome-encapsulated superoxide dismutase and catalase
128. Distribution studies of liposome-encapsulated glutathione administered to the lung
129. Pulmonary uptake of liposomal phosphatidylcholine upon intratracheal administration to rats
130. Studies on lung surfactant replacement in respiratory distress syndrome. Rapid film formation from binary mixed liposomes
131. Liposomes of dipalmitoylphosphatidylcholine associated with natural surfactant
132. Nebulization of sonicated phospholipid for treatment of respiratory distress syndrome (RDS) in infancy
133. Liposomes: a pulmonary perspective
134. Role of surfactant in alveolar defence against inhaled particles
135. Effects of a beta adrenergic drug and a secretolytic agent on regional mucociliary clearance in patients with COLD
136. Alveolar deposition of inhaled radio-aerosol particles in central and peripheral airway obstruction Methodologic conditions and clinical results
137. Flow limitation, cough, and patterns of aerosol deposition
138. Biodegradability of inhaled organic particles in patients with chronic bronchitis
139. Effects of atropine and methacholine on deposition and clearance of inhaled particles in the donkey
140. Measurement of tracheal and bronchial mucus velocities in man: Relation to lung clearance
141. Effect of inhaled salbutamol on mucociliary clearance in patients with chronic bronchitis
142. Deposition and clearance of radiolabelled monodisperse polystyrene spheres in the calf lung